Masaki Uchida

Mr. Masaki Uchida

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
LFLili Fitriani
Lili Fitriani
FDFauziyyah Dirfedli
Fauziyyah Dirfedli
Yori YuliandraYori Yuliandra
Yori Yuliandra
DSDwi Setyawan
Dwi Setyawan
MUMasaki Uchida
Masaki Uchida
EZErizal Zaini
Erizal Zaini

10 September 2026 in Molecules
Verified
Journal Article
Open access
PDF file
Ilma NugrahaniIlma Nugrahani
Ilma Nugrahani
YWYutong Wu
Yutong Wu
SFsofia fatmawati
sofia fatmawati
Hidehiro UekusaHidehiro Uekusa
Hidehiro Uekusa
RWRisang Wisesa
Risang Wisesa
MWMarlia Singgih Wibowo
Marlia Singgih Wibowo
Multicomponent antibiotic–anti-inflammatory systems have recently attracted considerable attention, as this combination is becoming a standard therapy for infectious diseases. This study aimed to develop a multicomponent system comprising norfloxacin (NOR), an old fluoroquinolone antibiotic, and niflumic acid (NIF), another old, poorly soluble anti-inflammatory drug, to improve the physicochemical properties, antibiotic potency, and anti-inflammation effect, as well as their safety. First, a phase diagram was constructed to ensure solid-state reaction and to predict its stoichiometry; subsequently, the multicomponent system was prepared by solvent-drop grinding. The product was analyzed by a series of thermal analyses and powder X-ray diffraction (PXRD). Next, Fourier-transform infrared spectroscopy and nuclear magnetic resonance elucidated the molecular interactions, and the final 3D structure was determined by single-crystal X-ray diffraction, followed by Hirshfeld surface analysis. Afterward, the solubility and chemical stability were assessed using high-performance liquid chromatography, and the physical stability of the multicomponent system was evaluated by PXRD. Antimicrobial potency against Gram-negative and Gram-positive bacteria, as well as anti-inflammatory activity in vivo, were also evaluated. The results demonstrated that a newly formed antibiotic–anti-inflammatory multicomponent system, named norfloxacin–niflumate (NORNIF), in a salt dihydrate form, significantly improved the stability and antibiotic potency of NOR, including against the resistant microbe, as well as the solubility and in vivo anti-inflammatory effect of NIF simultaneously. In addition, preliminary in silico studies using Swiss-ADME and ProTox-3 predicted that the salt was well absorbed in the gastrointestinal tract and could be classified as toxicity class 4 (non-toxic).